[{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$56.0 million","upfrontCash":"Undisclosed","newsHeadline":"Arena Pharmaceuticals Announces Launch of Longboard Pharmaceuticals With $56M Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Financing","leadProduct":"LP352","moa":"5-HT2C receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Longboard Pharmaceuticals","amount2":0.059999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Arena Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Longboard Pharmaceuticals \/ Arena Pharmaceuticals"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Longboard Pharmaceuticals Announces Pricing of Initial Public Offering ","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Public Offering","leadProduct":"LP352","moa":"5-HT2C receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Longboard Pharmaceuticals","amount2":0.080000000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Longboard Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longboard Pharmaceuticals Completes LP352 Multiple Ascending Dose Portion of Phase 1 Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"LP352","moa":"5-HT2C receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Longboard Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Longboard Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longboard Pharmaceuticals to Present Phase 1 Data for LP352 at the American Academy of Neurology Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"LP352","moa":"5-HT2C receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Longboard Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longboard Pharmaceuticals to Participate in Five Upcoming Epilepsy-Focused Conferences this Summer","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"LP352","moa":"5-HT2C receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Longboard Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longboard Pharmaceuticals Announces Positive Topline Data from a Phase 1 Clinical Study Evaluating Central Nervous System Pharmacokinetics and Pharmacodynamics of LP352 in Healthy Volunteers","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"LP352","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Longboard Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Evercore ISI","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Longboard Pharmaceuticals Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"LP352","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ Evercore ISI","highestDevelopmentStatusID":"8","companyTruncated":"Longboard Pharmaceuticals \/ Evercore ISI"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Evercore ISI","pharmaFlowCategory":"D","amount":"$23.0 million","upfrontCash":"Undisclosed","newsHeadline":"Longboard Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares in Public Offering of Common Stock","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"LP352","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ Evercore ISI","highestDevelopmentStatusID":"8","companyTruncated":"Longboard Pharmaceuticals \/ Evercore ISI"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Societal CDMO","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Societal CDMO Selected by Longboard Pharmaceuticals to Provide CDMO Services to Support Clinical Development of LP352","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Agreement","leadProduct":"LP352","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ Longboard Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Longboard Pharmaceuticals \/ Longboard Pharmaceuticals"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longboard Pharmaceuticals Completes Enrollment of Phase 1b\/2a PACIFIC Study Evaluating LP352 for the Treatment of Developmental and Epileptic Encephalopathies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"LP352","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Longboard Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Cantor","pharmaFlowCategory":"D","amount":"$172.5 million","upfrontCash":"Undisclosed","newsHeadline":"Longboard Pharmaceuticals Announces Commencement of Public Offering of Common Stock","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"Bexicaserin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0.17000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.23999999999999999,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ Cantor","highestDevelopmentStatusID":"8","companyTruncated":"Longboard Pharmaceuticals \/ Cantor"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b\/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Bexicaserin","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Longboard Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Cantor","pharmaFlowCategory":"D","amount":"$210.0 million","upfrontCash":"Undisclosed","newsHeadline":"Longboard Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"Bexicaserin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0.20999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.23999999999999999,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ Cantor","highestDevelopmentStatusID":"8","companyTruncated":"Longboard Pharmaceuticals \/ Cantor"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Cantor","pharmaFlowCategory":"D","amount":"$241.5 million","upfrontCash":"Undisclosed","newsHeadline":"Longboard Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"Bexicaserin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0.23999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.23999999999999999,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ Cantor","highestDevelopmentStatusID":"8","companyTruncated":"Longboard Pharmaceuticals \/ Cantor"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1 B\/2 A Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEES)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Bexicaserin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Longboard Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longboard Pharmaceuticals Announces Initiation of First-in-Human Phase 1 Clinical Study of LP659 in Adult Healthy Volunteers","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"LP659","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Longboard Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Longboard Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longboard Pharma Receives Breakthrough Therapy Designation for Bexicaserin (LP352)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Bexicaserin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Longboard Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longboard Pharmaceuticals: Positive Interim Results from PACIFIC Study on Bexicaserin","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Bexicaserin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Longboard Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longboard Pharmaceuticals Announces Positive Interim Results for Bexicaserin in DEEs","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"Bexicaserin","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"","graph3":"Longboard Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"","highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"13","companyTruncated":"Longboard Pharmaceuticals \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by Longboard Pharmaceuticals
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Market Place
Reset All
